Embecta (NASDAQ:EMBC) CEO Devdatt Kurdikar Acquires 30,000 Shares

Embecta Corp. (NASDAQ:EMBC) CEO Devdatt Kurdikar bought 30,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $4.70 per share, with a total value of $141,000.00. Following the completion of the purchase, the chief executive officer directly owned 804,919 shares of the company’s stock, valued at approximately $3,783,119.30. The trade was a 3.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Embecta Stock Up 7.6%

Embecta stock opened at $5.11 on Friday. The stock has a market cap of $289.53 million, a PE ratio of 3.45 and a beta of 0.81. The business’s 50-day moving average price is $3.46 and its two-hundred day moving average price is $6.42. Embecta Corp. has a 12-month low of $2.77 and a 12-month high of $15.55.

Embecta (NASDAQ:EMBC) last posted its earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm’s revenue was down 8.1% compared to the same quarter last year. During the same period last year, the company earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, analysts expect that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 27th. Embecta’s payout ratio is currently 2.70%.

Key Headlines Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively bought 70,000 Embecta shares worth approximately $334,200 on August 12. The purchases increased their individual holdings and may signal management confidence that the stock is undervalued. SEC insider transaction filing
• Neutral Sentiment: Several investor-rights firms are reminding shareholders that August 17, 2026, is the deadline to seek appointment as lead plaintiff for investors who purchased EMBC shares between November 25, 2025, and May 4, 2026. These announcements largely repeat the same lawsuit information rather than represent new company operating news. BFA Law class action reminder
• Negative Sentiment: The filed class action alleges that Embecta and certain executives violated federal securities laws by misrepresenting the commercial stability of its insulin pen-needle business and issuing misleading fiscal 2026 guidance. The claims follow a significant stock decline and could create legal costs, reputational damage and additional uncertainty around management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Hedge Funds Weigh In On Embecta

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. River Road Asset Management LLC increased its holdings in Embecta by 5.3% during the fourth quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock worth $40,587,000 after buying an additional 171,194 shares during the last quarter. State Street Corp boosted its stake in Embecta by 1.4% in the fourth quarter. State Street Corp now owns 2,360,626 shares of the company’s stock valued at $28,044,000 after acquiring an additional 31,796 shares during the last quarter. Jefferies Financial Group Inc. grew its position in shares of Embecta by 24.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock valued at $27,977,000 after acquiring an additional 470,096 shares during the period. Yacktman Asset Management LP grew its position in shares of Embecta by 3.2% during the 4th quarter. Yacktman Asset Management LP now owns 2,262,915 shares of the company’s stock valued at $26,883,000 after acquiring an additional 71,209 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Embecta by 13.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,233,869 shares of the company’s stock worth $14,658,000 after purchasing an additional 146,213 shares during the last quarter. 93.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on EMBC shares. Bank of America decreased their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research report on Friday, July 17th. BTIG Research cut shares of Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Finally, Mizuho reduced their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $11.00.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.